Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GNTA
GNTA logo

GNTA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.630
Open
0.610
VWAP
0.62
Vol
46.38K
Mkt Cap
14.76M
Low
0.600
Amount
28.74K
EV/EBITDA(TTM)
--
Total Shares
23.43M
EV
2.84M
EV/OCF(TTM)
--
P/S(TTM)
--
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Show More

Events Timeline

(ET)
2026-03-27
05:10:00
Genenta Science Enters €6M Financing Agreement with Sophia High Tech
select
2026-03-24 (ET)
2026-03-24
05:30:00
Genenta Science Explores Collaboration Opportunities for Biotechnology Platform
select
2026-01-27 (ET)
2026-01-27
05:30:00
Genenta Science Plans to Acquire Majority Stake in ATC
select
2025-11-24 (ET)
2025-11-24
05:09:37
Genenta Science Offers Update on TEM-GBM Research Study
select
2025-10-24 (ET)
2025-10-24
05:06:19
Genenta Science and Anemocyte Form Partnership to Enhance Plasmid DNA Technology
select
2025-07-01 (ET)
2025-07-01
05:22:04
Genenta Science announces follow-up observations in glioblastoma study
select
2025-05-07 (ET)
2025-05-07
07:28:25
Genenta Science, Anemocyte announce collaboration
select
2025-03-19 (ET)
2025-03-19
09:31:57
Genenta Science announces EUR 20M financing to expand pipeline
select
2025-01-09 (ET)
2025-01-09
05:46:06
Genenta Science announces amendment to pact with AGC Biologics
select

News

Newsfilter
8.5
03-27Newsfilter
Genenta Acquires Sòphia High Tech to Advance Strategic Consolidation
  • Strategic Acquisition: Genenta Science S.p.A. announced the acquisition of Italian Sòphia High Tech, planning to invest a total of €6 million through two reserved capital increases to achieve a controlling stake, thereby enhancing its market position in biotechnology and defense sectors.
  • Performance-Driven Investment: The transaction will be executed in two phases, with the second phase contingent on Sòphia's performance milestones, ensuring effective use of funds to significantly scale production capacity and accelerate technological differentiation.
  • Industry Leadership: Since its founding in 2013, Sòphia High Tech has completed over 530 advanced projects, serving top aerospace and defense organizations including the European Space Agency, demonstrating strong profitability and ongoing EBITDA growth potential.
  • Technological Innovation and Market Expansion: The acquisition will drive investments in Sòphia's advanced manufacturing technologies, particularly in metal 3D printing and precision machining, further solidifying its leadership in Italy's deep-tech sector to meet growing international demand.
Yahoo Finance
8.5
03-13Yahoo Finance
Genenta Science Transforms to Saentra Forge, Focused on Strategic Industrial Consolidation
  • Company Renaming: Genenta Science S.p.A. is transforming into Saentra Forge, focusing on strategic industrial consolidation in biotech, defense, aerospace, and Italian national security technologies, which is expected to enhance its market competitiveness and industry influence.
  • CEO Appointment: CEO Pierluigi Paracchi has been appointed to the Board of Guarantors of the Italian Academy for Advanced Studies, which not only elevates his personal prestige but also strengthens the company's ties with academia in Italy and the U.S., promoting cultural and research exchanges.
  • Board Composition: The Board of Guarantors of the Italian Academy consists of twelve members, with six appointed by the Italian government and six by Columbia University, aimed at supporting the Academy's academic and cultural excellence and further solidifying academic ties between Italy and the U.S.
  • Strategic Goals: Saentra Forge will focus on acquiring privately held companies in sectors related to Italian national security, including cybersecurity and biosecurity, and is expected to drive long-term growth by integrating resources and technologies in these critical areas.
Yahoo Finance
4.5
02-28Yahoo Finance
Genenta Science Shifts Focus to Defense Sector
  • Strategic Shift: Genenta Science SPA announced a pivot from biotech to defense and national security, with an extraordinary shareholders meeting scheduled for March 26, marking a significant decision in response to changing market dynamics.
  • Acquisition Targets: The company aims to acquire profitable private Italian businesses generating around €5 million in annual EBITDA and has begun scouting for targets, having struck a deal to acquire ATC, a tactical rifles and special-forces weapon systems maker, contingent on meeting specific performance milestones.
  • Financial Projections: ATC projects €2.0 million in EBITDA for 2026, expecting to double this in 2027, which will provide robust financial support for Genenta's new business model and enhance its market position.
  • Ongoing Biotech Investment: Despite the shift to defense, Genenta plans to continue its biotech programs through partnerships, demonstrating the company's flexibility and foresight in diversifying its business strategy.
Newsfilter
8.5
02-27Newsfilter
Genenta Science Transforms into Saentra Forge, Appoints New Board Member
  • New Board Appointment: Genenta Science has appointed Paolo Salvato to the Board of Directors of ATC, marking the company's initial entry into defense technology manufacturing, which is expected to enhance its strategic position in the defense sector.
  • Acquisition Opportunity Evaluation: The company is evaluating majority-control acquisition opportunities in regulated national-security sectors, aiming to build a next-generation strategic industrial consolidator to support technology and scale-up initiatives.
  • Biotech Progress: The company announced that its manuscript on clinical findings from the Glioblastoma Multiforme trial has been accepted for publication by Nature Medicine, which is expected to provide significant validation of its scientific and clinical efforts, thereby enhancing market credibility.
  • Capital Market Potential: As a publicly listed company, Genenta Science plans to access capital through its Nasdaq listing to support its strategy of acquiring profitable industrial businesses, enhancing financial flexibility and driving long-term value creation.
Benzinga
4.5
01-27Benzinga
Genenta Science Transitions to Defense Sector Consolidator
  • Strategic Shift: Genenta Science announced its rebranding to Saentra Forge S.p.A. and plans to acquire privately held businesses with approximately €5 million in EBITDA, marking a strategic pivot towards the defense sector.
  • Funding Commitment: The company has entered into an agreement to provide €5.1 million in funding to ATC, which is projected to achieve around €4 million in revenue by 2026 and double its EBITDA by 2027, highlighting the growth potential of this new direction.
  • Clinical Milestones: Genenta has reached key clinical milestones aimed at establishing partnerships with major pharmaceutical and biotech firms to accelerate development, improve market access, and enhance strategic value.
  • Financial Outlook: Despite a 68.29% decline in stock over the past year, shares are currently trading 87.5% above the 20-day simple moving average, indicating short-term strength, with expectations of cash and equivalents reaching approximately $33 million by the end of 2025.
Benzinga
2.0
01-27Benzinga
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
  • Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
  • Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
  • Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
  • Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.
Wall Street analysts forecast GNTA stock price to rise
1 Analyst Rating
Wall Street analysts forecast GNTA stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
7.00
Averages
7.00
High
7.00
Current: 0.000
sliders
Low
7.00
Averages
7.00
High
7.00
No data

No data

Valuation Metrics

The current forward P/E ratio for Genenta Science SPA (GNTA.O) is -2.46, compared to its 5-year average forward P/E of -8.73. For a more detailed relative valuation and DCF analysis to assess Genenta Science SPA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.73
Current PE
-2.46
Overvalued PE
-3.05
Undervalued PE
-14.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.39
Undervalued EV/EBITDA
-10.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
25.80
Current PS
0.00
Overvalued PS
85.21
Undervalued PS
-33.61

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

I need all stocks that about to halt?
Intellectia · 22 candidates
Price Change Pct: $-100.00 - $-8.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASENews Driver: Positive, Negative
Ticker
Name
Market Cap$
top bottom
ITRM logo
ITRM
Iterum Therapeutics PLC
1.90M
BUR logo
BUR
Burford Capital Ltd
906.24M
LTRN logo
LTRN
Lantern Pharma Inc
12.53M
ONCO logo
ONCO
Onconetix Inc
1.35M
AMPG logo
AMPG
Amplitech Group Inc
45.60M
SLND logo
SLND
Southland Holdings Inc
66.02M
best stock today for day trading
Intellectia · 3393 candidates
Price: $1.00 - $200.00Volume: >= 50,000List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
RR logo
RR
Richtech Robotics Inc
1.12B
NVDA logo
NVDA
NVIDIA Corp
4.61T
INTC logo
INTC
Intel Corp
218.01B
NUWE logo
NUWE
Nuwellis Inc
6.31M
AAL logo
AAL
American Airlines Group Inc
9.10B
F logo
F
Ford Motor Co
55.04B
take me to stock radar
Intellectia · 53 candidates
Region: USPrice: $1.00 - $30.00Volume: >= 1,000,000Price Change Pct: $-25.00 - $25.00Relative Vol: >= 2List Exchange: XNYS, XNAS
Ticker
Name
Market Cap$
top bottom
SATL logo
SATL
Satellogic Inc
729.00M
HUYA logo
HUYA
HUYA Inc
1.01B
GNTA logo
GNTA
Genenta Science SPA
30.70M
ATOM logo
ATOM
Atomera Inc
105.50M
BAER logo
BAER
Bridger Aerospace Group Holdings Inc
173.85M
UROY logo
UROY
Uranium Royalty Corp
683.86M

Whales Holding GNTA

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Genenta Science SPA (GNTA) stock price today?

The current price of GNTA is 0.6287 USD — it has decreased -0.16

What is Genenta Science SPA (GNTA)'s business?

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.

What is the price predicton of GNTA Stock?

Wall Street analysts forecast GNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNTA is7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Genenta Science SPA (GNTA)'s revenue for the last quarter?

Genenta Science SPA revenue for the last quarter amounts to NaN USD, decreased

What is Genenta Science SPA (GNTA)'s earnings per share (EPS) for the last quarter?

Genenta Science SPA. EPS for the last quarter amounts to USD, decreased

How many employees does Genenta Science SPA (GNTA). have?

Genenta Science SPA (GNTA) has 13 emplpoyees as of March 31 2026.

What is Genenta Science SPA (GNTA) market cap?

Today GNTA has the market capitalization of 14.76M USD.